Biodevice-CRO is a MEDVIA project uniting three very different, but complementary, Flemish companies: ICsense, Comate, and Antleron. This unique partnership aims to provide life science actors with customizable, modular bioprocess solutions through a collaborative Contract Research Organization (CRO) model. These smart solutions – the biodevice based on an integrated chip, biofluidic cartridge, and functional device – will enable fast-track development of personalized medicines and improved diagnostics.
OHMX.bio provides innovative omics solutions using state-of-the-art sequencing and mass spectrometry platforms. Specializing in expression analysis (RNA-seq and RIBO-seq) and epigenetic profiling, as well as companion diagnostics, the company uses second- and third-generation sequencing technology to enable scientific insights and build assays for better drug and therapy development. With both a wet lab and dry lab in house, OHMX.bio offers a full-circle service to biotech and pharma partners.
Byteflies is on a mission to make virtual care available to all. The Belgian company has developed a platform for remote patient monitoring solutions, to save precious time for healthcare providers, reduce hospitalization costs, and boost the quality of life for patients. The aim is to aid the transition from fragmented to connected healthcare, enabling a continuum of care through virtual solutions.
CoMoveIT is a striking example of how visionary ideas can be turned into life-changing innovations once the right technology becomes available. We spoke with CoMoveIT’s CTO, Sotirios Gakopoulos, about the Belgian company’s unique solution to improve the mobility of patients with complex movement disorders, like cerebral palsy.
Flash radiation has the potential to become a revolution in radiation therapy. An incredibly promising cancer treatment that limits the damage to surrounding tissue, it is currently in the pre-clinical stage. MEDVIA-funded project eFlash2D is working to assure that dosing is ready when flash radiation enters clinical trials.
There is a lot of money being invested in health innovation in Flanders, yet companies consistently run into the same roadblocks on their path to market. MEDVIA’s mission is to bring people together to address these barriers, and to facilitate the creation of complex collaborations between different members of the ecosystem for truly innovative patient solutions.
After recovering from metastatic colon cancer, Stefan Gijssels became a patient advocate dedicated to improving the healthcare system that saved his life. As Chair of the Belgian Patient Expert Center (PEC), he has helped to establish a training program turning patients into patient experts who can provide stakeholders like hospitals and companies with valuable insights during the innovation process.
Ghent, Belgium, 20 January 2022 – Dr. Ann Van Gysel has been appointed as CEO of the flanders.healthTech spearhead cluster. She will lead the cluster, which brings together personalized and digital medicine and healthcare technology in Flanders, and supports the development and implementation of new technologies in the Flemish healthcare sector.
Collaboration is vital for science. Without cross-pollination of ideas and talent, progress would be excruciatingly slow in both industry and academia. Networking opportunities, like the annual Knowledge for Growth event and Science for health, stimulate research collaboration by connecting people. So, what’s the role of a cluster organization in all this? BioVox spoke with flanders.bio representatives Pascale Engelen and Katrien Lorré to find out.